Trial Profile

A Phase 1 Study of Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Magrolimab (Primary)
Indications Brain cancer; Ependymoma
Focus Adverse reactions
Acronyms PNOC025

Most Recent Events

11 Oct 2024 Status changed from suspended to completed.
20 Feb 2024 Status changed from recruiting to suspended (FDA Partial Clinical Hold).
21 Mar 2022 Planned initiation date changed from 28 Feb 2022 to 15 Apr 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com